Matrix metalloproteinases and their inhibitors in canine mammary tumors
2011

Matrix Metalloproteinases and Their Inhibitors in Canine Mammary Tumors

Sample size: 35 publication Evidence: moderate

Author Information

Author(s): Aresu Luca, Giantin Mery, Morello Emanuela, Vascellari Marta, Castagnaro Massimo, Lopparelli Rosa, Zancanella Vanessa, Granato Anna, Garbisa Spiridione, Aricò Arianna, Bradaschia Alice, Mutinelli Franco, Dacasto Mauro

Primary Institution: Università degli Studi di Padova

Hypothesis

Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) are involved in the progression of malignant canine mammary tumors.

Conclusion

MMP-9, MMP-2, and MT1-MMP play significant roles in malignant canine mammary tumors, and their levels could serve as biomarkers for tumor progression.

Supporting Evidence

  • MMP-2 and MMP-9 were expressed at both mRNA and protein levels in tumor samples.
  • 94% of carcinoma samples showed active MMP-2, compared to 17% of benign tumors.
  • Immunohistochemical reactions for MMP-2 were stronger in malignant tumors than in benign tumors.
  • Active MMP-9 was found in the plasma of all tested dogs with tumors.

Takeaway

This study looked at how certain proteins related to tumors in dogs can help us understand and predict cancer growth.

Methodology

The study involved tissue sampling from 35 dogs, gene expression analysis using qRT-PCR, and immunohistochemistry to evaluate protein levels.

Limitations

The study may not represent all types of canine mammary tumors due to the specific sample selection.

Participant Demographics

Median age of dogs was 9.9 years, with 13 adenomas and 22 carcinomas.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1746-6148-7-33

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication